BioArctic
Five-year data of continuous Leqembi® treatment show increasing benefit over time
BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today presented new five-year data from the Clarity AD study and its long-term…
Company newsroom
2 releases
BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today presented new five-year data from the Clarity AD study and its long-term…
BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today announced that Leqembi Pen, the subcutaneous formulation of lecanemab, has been…